Class III Antiarrhythmic Effects of Dofetilide in Rabbit Atrial Myocardium

Gwilt M. , Arrowsmith J. , Blackburn K. , Burges R UK-68,798: A novel, potent and highly selective class III antiarrhythmic agent which blocks potassium channels in cardiac cells. J Pharmacol Exp Ther 256: 318, 1991

Carmeliet E. Effect of UK 68,798 on delayed K⁺ currents in cardiac myocytes. Circulation (Suppl 2) 84: II-176, 1991

Rasmussen H. , Allen M. , Blackburn K. , Butrous G. , Dalrymple H. Dofetilide, a novel class III antiarrhythmic agent. J Cardiovasc Pharmacol 20(suppl 2): S96, 1992

Gwilt M. , Blackburn K. , Burges R. , Higgins A. , Milne A. , Solca A. Electropharmacology of UK-68,798, a new class III agent, in anesthetised dogs. Eur J Pharmacol 215: 137, 1992

Jurkiewicz N. , Sanguinetti M. Rate-dependent prolongation of cardiac action potentials by a methanesulfonanilide class III antiarrhythmic agent. Circ Res 72: 75, 1993

Krafte D. , Volberg W. Voltage dependence of cardiac delayed rectifier block by methanesulfonamide class III antiarrhythmic agents. J Cardiovasc Pharmacol 23: 37, 1993

Zuanetti G. , Corr P. Antiarrhythmic efficacy of a new class III agent, UK-68,798, during chronic myocardial infarction: evaluation using three-dimensional mapping. J Pharmacol Exp Ther 256: 325, 1991

Echt D. , Lee J. , Murray K. , Vorperian V A randomised, double-blind, placebo-controlled dose-ranging study of intravenous UK 68,798 (Dofetilide) in patients with inducible sustained ventricular tachyarrhythmias. Circulation (suppl 2) 84: II-714, 1991

Thomsen P. , Bashir Y. , Kingma J Dofetilide in the treatment of sustained monomorphic ventricular tachycardia. Eur Heart J 13: 304, 1992

Connelly D. , Thomsen P. , Camm A Efficacy and safety of dofetilide, a novel class III antiarrhythmic agent, in atrioventricular nodal reentrant tachycardia. Eur Heart J 13: 304, 1992

Brachmann J. , Haverkamp W. , Johns J. , Zehender M. , Kingma H. , Wiecha J. The efficacy and safety of oral dofetilide in patients with sustained ventricular tachycardia. Circulation 86: I-265, 1992

Suttorp M. , Polak P. , Van't-Hof A. , Rasmussen H. , Dunselman P. , Kingma J. Efficacy and safety of a new selective class III antiarrhythmic agent dofetilide in paroxysmal atrial fibrillation or atrial flutter. Am J Cardiol 69: 417, 1992

Montero M. , Beyer T. , Brachmann J. , Kubler W. Electrophysiological effects of the new class III substance UK-68,798 on rabbit isolated sinus node and atrium (Ger Abstract) Z Kardiol 80(suppl 3): 55, 1991

Tande P. , Björnstad H. , Yang T. , Refsum H. Rate-dependent class HI antiarrhythmic action, negative chronotropy, and positive inotropy of a novel I_K blocking drug, UK-68,798: potent in guinea pig but no effect in rat myocardium. J Cardiovasc Pharmacol 16: 401, 1990

Josephson I. , Sanchez-Chapula J. , Brown A. Early outward current in rat single ventricular cells. Circ Res 54: 157, 1984

Chadwick C. , Ezrin A. , O'Connor B Identification of a specific radioligand for the cardiac rapidly activating delayed rectifier K⁺ channel. Circ Res 72: 707, 1993

Varro A. , Lathrop D. , Hester S. , Nanasi P. , Papp J. Ionic currents and action potentials in rabbit, rat and guinea pig ventricular myocytes. Basic Res Cardiol 88/2: 93, 1993

Sedgwick M. , Rasmussen H. , Cobbe S. Effects of the class III antiarrhythmic drug dofetilide on ventricular monophasic action potential duration and QT interval dispersion in stable angina pectoris. Am J Cardiol 70: 1432, 1992

Tham T. , MacLennan B. , Burke M. , Harron D. Pharmacodynamics and pharmacokinetics of the class III antiarrhythmic agent dofetilide (UK-68,798) in humans. J Cardiovasc Pharmacol 21: 507, 1993

Hondeghem L. , Snyders D. Class III antiarrhythmic agents have a lot of potential but a long way to go: reduced effectiveness and dangers of reverse use dependence. Circulation 81: 686, 1990

Colatsky T. , Singh B. Potassium channel blockers as antiarrhythmic agents. In Singh B. , Dzau V. , Vanhoutte P. , Woosley R. (eds). Cardiovascular Pharmacology and Therapeutics. Churchill Livingstone New York, pp. 675–688, 1994

Baskin E. , Serik C. , Wallace A Effects of new and potent methanesulfonanilide class III antiarrhythmic agents on myocardial refractoriness and contractility in isolated cardiac muscle. J Cardiovasc Pharmacol 18: 406, 1991

Beyer T. , Marschang H. , Kübler W. , Brachmann J. Reverse “use-dependent” class III effects of UK-68,798 in relation to extracellular potassium concentration. Eur Heart J (suppl) 13: 303, 1992

Baskin E. , Lynch J. Comparative effects of increased extracellular potassium and pacing frequency on the class III activities of methanesulfonanilide I_Kr blockers dofetilide, d-sotalol, E-4031, and MK-499. J Cardiovasc Pharmacol 24: 199, 1994

Wang Z. , Pelletier C. , Talajic M. , Nattel S. Effects of flecainide and quinidine on human atrial action potentials: role of rate-dependence and comparison with guinea pig, rabbit, and dog tissue. Circulation 82: 274, 1990

Wang Z. , Page P. , Nattel S. Mechanism of flecainide's antiarrhythmic action in experimental atrial fibrillation. Circ Res 71: 271, 1992

Wang J. , Bourne G. , Wang Z. , Villemaire C. , Talajic M. , Nattel S. Comparative mechanisms of antiarrhythmic drug action in experimental atrial fibrillation: importance of use-dependent effects on refractoriness. Circulation 88: 1030, 1993

Wang Z. , Fermini B. , Nattel S. Mechanism of flecainide's rate dependent actions on action potential duration in canine atrial tissue. J Pharmacol Exp Ther 267: 575, 1993

Knilans T. , Lathrop D. , Nánási P. , Schwartz A. , Varró A. Rate and concentration-dependent effects of UK-68,798, a potent new class III antiarrhythmic, on canine Purkinje fiber action potential duration and Vmax. Br J Pharmacol 103: 1568, 1991

Wang Z. , Fermini B. , Nattel S. Delayed rectifier outward current and repolarization in human atrial myocytes. Circ Res 73: 276, 1993

Duan D. , Fermini B. , Nattel S. Potassium channel blocking properties of propafenone in rabbit atrial myocytes. J Pharmacol Exp Ther 264: 1113, 1993

Yang T. , Tande P. , Lathrop D. , Refsum H. Class III antiarrhythmic action by potassium channel blockade: dofetilide attenuates hypoxia induced electromechanical changes. Cardiovasc Res 26: 1109, 1992

Wang J. , Feng J. , Nattel S. Class III antiarrhythmic drug action in experimental atrial fibrillation. Circulation 90: 2032, 1994

Carmeliet E. Voltage- and time-dependent block of the delayed K⁺ current in cardiac myocytes by dofetilide. J Pharmacol Exp Ther 262: 809, 1992

Krafte D. , Volberg W. Voltage dependence of cardiac delayed rectifier block by methanesulfonamide class III antiarrhythmic agents. J Cardiovasc Pharmacol 23: 37, 1994

Ohler A. , Amos G.J. , Wettwer E. , Ravens U. Frequency-dependent effects of E-4031, almokalant, dofetilide and tedisamil on action potential duration: no evidence for “reverse use dependent” block. Naunyn-Schmiedebergs Arch Pharmacol, 349: 602, 1994

Meinertz T. Clinical implications of new insights into mechanism of antiarrhythmic drug action. J Cardiovasc Pharmacol 20 (supp 2): S23, 1992